| INTRODUCTION
Biological therapy with tumour necrosis factor-a (TNFa) antagonists such as infliximab and adalimumab, alone or in combination with immunomodulators, is one of the most effective treatments in inducing and maintaining clinical remission in patients with Crohn's disease (CD), and has been shown to decrease the risks of hospitalisation and surgery. [1] [2] [3] [4] [5] In the absence of head-to-head trials,
there is an unmet need among patients and physicians to better understand the relative effectiveness and safety of different TNF-a antagonists. Current decisions on the choice of TNFa antagonists are primarily driven by patient and clinician preferences, and in some countries, on insurance coverage; however, there are differences in the dosing and route of administration of these agents, and hence, there may be differences in effectiveness and safety. 6 Indirect treatment comparison network meta-analysis has shown no difference in rates of induction and maintenance of remission between infliximab and adalimumab, although these short-term trials had restrictive inclusion criteria, and limited generalisability. 7, 8 Prior observational comparative studies have shown variable results.
Using a U.S. administrative claims database, we had previously observed that infliximab use may be associated with a lower risk of CD-related hospitalisation (hazard ratio, 0.80), abdominal surgery (HR, 0.76) and corticosteroid use (HR, 0.85), as compared to adalimumab. 9 In contrast, in a retrospective cohort study using Medicare, Osterman et al observed no significant differences in the risks of hospitalisation or surgery between infliximab-and adalimumabtreated patients with CD, though in a subset of younger patients, infliximab use was associated with a lower risk of surgery compared to adalimumab (odds ratio [OR] , 0.66). 10 However, both of these studies were limited by potential misclassification of prior TNF-a antagonist exposure due to short observational time prior to starting TNFa antagonists.
Therefore, we studied the comparative effectiveness and safety of infliximab and adalimumab in truly biologic-na€ ıve adults with CD, using a population-based, propensity-score matched real-life cohort study based on the Danish nationwide disease and treatment registries.
2 | ME TH ODS Figure 1 shows the flow of patients for identification of the cohort.
The study was approved by the Danish Data Protection Agency.
Ethics approval is not required for registry-based research in Denmark.
| Exposures and outcomes of interest
The primary exposures of interest were prescription of infliximab or adalimumab for CD. We considered patients as being continuously | 597
The primary outcomes of interest were:
Effectiveness outcomes
1. All-cause hospitalisation.
2.
Crohn's disease-related hospitalisation, with CD either as the primary diagnosis, or as a secondary diagnosis if the primary diagnosis was related to a gastrointestinal symptom (abdominal pain, diarrhoea, nausea, vomiting, constipation, gastrointestinal bleeding).
3.
Major abdominal surgery (identified using established procedural codes). 14 
4.
Corticosteroid prescription, occurring at least 60 days after the start of TNFa antagonist (to minimise confounding by disease severity).
Safety outcomes
5. Hospitalisation for serious infections as primary diagnosis (Table S1) 15
If the index TNFa antagonist prescription was started during an inpatient hospitalisation, then that hospitalisation was not counted as an outcome; only inpatient admissions occurring >23 hours after drug initiation were regarded as outcomes (to avoid misclassifying observation visits for infliximab infusions as outcome). 
| Covariates of Interest

| Statistical analysis
To take into account potential confounders, our primary analysis used variable 2:1 propensity score matching using the nearest neighbour caliper matching with a caliper width of 0.2. 17 We calculated the propensity scores as the predicted probability of starting treatment with TNFa antagonist conditional on variables thought to be either confounders or predictors for the outcome. These variables included demographic variables (age at initiation of TNFa antagonist, sex), disease-related characteristics (age at disease onset, disease duration, prior abdominal surgery), disease severity, measures of healthcare utilisation (all-cause or CD-related outpatient visit, emergency department visit or hospitalisation, endoscopy and/or radiology procedure within preceding 5 years), comorbidity burden (based on Charlson-Deyo index) 18 and medication use (all and IBD-related; Table S2 ). We measured the standardised difference of each covariate in the propensity score model using logistic regression, and variables were considered to be different across treatment if after propensity score matching the standardised difference was greater than 10%. Using Cox regression models, we estimated HR with 95% Analyses were carried out using Phreg procedure in SAS version 9.4 (Cary, NC). We considered differences to be statistically significant when the 95% CIs did not overlap 1.0 or when the P < .05 (all tests were two sided).
| Sensitivity analyses
Since propensity score matching results in loss of sample size, we performed sensitivity analysis using propensity score adjustment that allowed us to retain all identified patients in the analysis and increase statistical power. 19 To account for potential differences in underlying disease severity, we performed sensitivity analysis after restricting to patients classified as having "disabling" disease based on surrogate measures captured in the modified Beaugerie index. 16 3 | RESULTS
| Characteristics of patients
We identified 2908 biologic-na€ ıve patients with CD who started their first TNFa antagonist between 2005 and 2014, of whom 434
were treated with adalimumab and 2474 with infliximab. (Table 2 ).
| Stratified analysis-TNFa antagonist and combination therapy
On stratified analysis, in the propensity score matched analysis, there were no significant differences between adalimumab-and infliximabtreated patients with either TNFa antagonist monotherapy or combination therapy, though a trend favouring adalimumab-based therapy was observed in both strata (Table 3) . On propensity score adjusted analysis, a beneficial effect of adalimumab over infliximab in reducing all-cause and IBD-related hospitalisation was observed only in the strata of patients on concomitant immunomodulator therapy.
| Sensitivity analysis-patients with "Disabling" disease
On restricting analyses to patients classified as having "disabling" disease based on the modified Beaugerie index, no significant SINGH ET AL.
| 599 differences in effectiveness and safety was observed between patients started on adalimumab or infliximab as first biological agent (Table 4) . Approximately 43% of adalimumab-treated patients and 44% of infliximab-treated patients classified as having disabling disease were on combination therapy.
| DISCUSSION
In this Danish nationwide cohort study of 2908 biologic-na€ ıve patients with CD (312 patients treated with adalimumab and 512 patients with infliximab in the propensity score matched cohort), we observed that adalimumab and infliximab were comparable in terms of risk of IBD-related hospitalisation, major abdominal surgery, new initiation of corticosteroids and serious infections, although adalimumab-treated patients had lower risk of all-cause hospitalisation.
These results were stable on sensitivity analysis using propensity score adjusted analysis. This difference was comparable in strata of CD, Crohn's disease; IQR, interquartile range; n, number of patients; pts, patients; SD, standard deviation; TNF-tumour necrosis factor. Bold represents statistically significant differences between groups.
Austria, Narula et al observed comparable rates of induction and maintenance of overall and steroid-free clinical remission with adalimumab and infliximab. 20 Similarly, in a single centre prospective registry based study of 906 biologic-na€ ıve patients with CD, from Major abdominal surgery adalimumab-treated patients with CD, though the summary estimate favoured infliximab. 10 However, both of these US claims-based studies were at risk of misclassification of "biologic-na€ ıve" status; due to short duration of follow-up since patients in the US healthcare system frequently switch health insurances, it was not possible to correctly classify patients as being truly biologic-na€ ıve patients. This would conceivably bias results against adalimumab since it was approved later, at a time when a proportion of patients may have already failed infliximab, and adalimumab was being used as a second anti-TNF agent. Since the response to a second TNF-a antagonist is often inferior to that of the first TNF-a antagonist, it may explain the potentially lower effectiveness of adalimumab in these studies. 23 In contrast to the US claims-based studies, in the Danish population-based cohort, we were able to longitudinally follow all patients through the course of their disease with high accuracy, minimising risk of misclassifying exposures. In the only other populationbased study from Manitoba, Canada, Targownik et al observed that among patients with successful induction therapy, there was no significant difference in 1-year rates of IBD-related surgery (adalimumab vs infliximab: 11% vs 12%), hospitalisation (12% vs 14%), reinitiation of corticosteroids (28% vs 31%) or drug discontinuation (32% vs 35%); these results were stable on multivariable analysis though propensity score matching was not performed. 24 These findings are in contrast to prior observations in the Danish cohort suggesting that infliximab was associated with lower risks of hospitalisation and serious infections, as compared to adalimumab, in patients with ulcerative colitis, particularly in a stratum of sicker patients on concomitant immunomodulators. 25 Ulcerative colitis, particularly severe disease, often requires a higher TNFa antagonist trough level, as compared to CD. 26 Given dosing flexibility as well as weight-based dosing of infliximab, it is possible that infliximab was superior to adalimumab in patients with severe ulcerative colitis due to higher systemic exposure.
Lower rates of all-cause hospitalisation in adalimumab-treated patients, as compared to infliximab-treated patients are challenging to interpret considering lack of differences in other more CD-specific related outcomes. This may be related to unmeasured confounding or differences in treatment patterns and preferences. For example, patients with perianal disease may be more likely to be prescribed infliximab than adalimumab, and these patients may be intrinsically more likely to have higher hospitalisation-related burden. Due to lack of sensitivity of claims codes for perianal disease, we were unable to explore the hypothesis in detail. Alternatively, since patients treated with infliximab have greater healthcare contact due to in-hospital administration of the medication, these patients may be more likely to have shorter time to first all-cause hospitalisation.
Our findings suggesting comparability of adalimumab and infliximab in patients on TNFa antagonist monotherapy, but favouring adalimumab over infliximab in patients on concomitant immunomodulator therapy in the propensity cohort adjusted analysis, was unex- These findings must be interpreted with caution, given the limitations associated with our study design. First, this was an observational, claims-based study, not an interventional study, and hence, there may be unmeasured confounders across groups. The potential for unmeasured confounding by severity is of particular importance, since we were not able to objectively assess endoscopic or biochemical disease activity. Similarly, due to poor performance of claims codes for perianal disease, we were unable to adjust for the same in our analysis. We tried to minimise this risk by performing propensity-score matching. The overall prevalence of measures of "disabling" CD was comparable between adalimumab-and infliximab-treated patients. Second, we were unable to account for the impact of therapeutic drug monitoring or dose escalation, practices which have become more common recently, given inaccurate estimation using administrative databases. Third, both baseline covariates and outcomes were measured using administrative claims codes and may be subject to errors. Definitions for some covariates and outcomes, such as combination immunosuppressive therapy, treatment discontinuation, etc. were chosen using best investigator judgement, and have not been validated. Finally, slight differences were observed in the propensity score matched and propensity score adjusted analyses; the former method is generally believed to be more robust. 29 In conclusion, using a population-based, propensity-matched cohort study, we observed that adalimumab and infliximab have comparable effectiveness and safety in a real-life setting of biologic- 
